Medical News

RSS

Dabigatran etexilate prevents recurrent VTE with less bleeding than warfarin

Boehringer Ingelheim today announced very positive results from their landmark RE-COVER™ study – the most advanced trial programme assessing a novel oral anticoagulant in development for acute venous thromboemolism (VTE) treatment – presented at the American Society of Hematology Annual Meeting1 and published in the New England Journal of Medicine online.

7 Dec 2009

New oral drug is safe and effective to combat clotting disorder

A new study provides welcome news for patients with a common clotting disorder known as venous thromboembolism (VTE).

7 Dec 2009

Galapagos NV issues new shares

Galapagos NV (Euronext: GLPG) announced today a capital increase of EUR 902,564 and the issue of 225,641 new shares as a result of the exercise of warrants by Galapagos warrant holders, including CEO Onno van de Stolpe.

7 Dec 2009

UHC recognizes 10 AMC members for their achievements in Supply Chain Optimization Program

The University HealthSystem Consortium (UHC) recognized 10 academic medical center (AMC) members for their achievements in UHC's Supply Chain Optimization Program.

7 Dec 2009

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

Gloucester Pharmaceuticals announced today the presentation of positive data from an analysis of ISTODAX® (romidepsin) in a subset of patients from Gloucester’s registration study in cutaneous T-cell lymphoma (CTCL) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, LA.

7 Dec 2009

J&JPRD announces clinical results of new oral anticoagulant therapy for venous thromboembolism

Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD), announced today that results from the Phase III EINSTEIN-Extension (EXT) clinical trial of the novel oral anticoagulant rivaroxaban showed a significant reduction in the risk of recurrent symptomatic venous thromboembolism (VTE), compared to placebo, in patients who have been treated for a previous deep vein thrombosis (DVT) or pulmonary embolism (PE).

7 Dec 2009

Computer search algorithms identify FDA-approved drugs that could be the basis for new medicines

A massive, data-crunching computer search program that matches fragments of potential drug molecules to the known shapes of viral surface proteins has identified several FDA-approved drugs that could be the basis for new medicines -- if emerging viruses such as the H5N1(avian flu) or H1N1/09 (swine flu) develop resistance to current antiviral therapies -- according to a presentation at the American Society for Cell Biology (ASCB) 49th Annual Meeting, Dec. 5-9, 2009 in San Diego.

7 Dec 2009

AHF hosts free rapid HIV testing in conjunction with Faithful Central Bible Church

In observation of World AIDS Day 2009, AIDS Healthcare Foundation (AHF), the largest global AIDS group which currently provides more than 15,000 free HIV and STD tests annually in California via its community-based testing programs, is hosting a day of free rapid HIV testing in conjunction with Faithful Central Bible Church this Sunday December 6th starting at 6:00am going until 4:00pm at the congregation’s church in Inglewood (321 Eucalyptus Street, Inglewood, 90301).

7 Dec 2009

CDC announces the start of National Influenza Vaccination Week

Today the Centers for Disease Control and Prevention (CDC) announced the start of National Influenza Vaccination Week. While the week was designed to highlight the importance of flu vaccinations, it also brings to light the importance of taking additional steps to keep you and your family healthy during the peak cold and flu season of December, January and beyond.

7 Dec 2009

Positive clinical data from Phase II study of elacytarabine in patients with AML reported

Clavis Pharma ASA announces that positive clinical data from its Phase II study with its lead cancer product candidate elacytarabine in patients with late-stage acute myeloid leukaemia (AML) was presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, LA, USA.

7 Dec 2009

SU2C awards $9.68 million to support high-risk cancer research

Stand Up To Cancer (SU2C) announced today that it is awarding $9.68 million to support high-risk/high-reward cancer research conducted by 13 young scientists.

7 Dec 2009

Anticoagulants used to prevent clots in placental blood vessels ineffective, reveals research

Blood clotting, or coagulation, is an important process that prevents excessive bleeding when a blood vessel is injured. Sometimes, however, clots form on the inside of vessels without an obvious injury or do not dissolve naturally, a potentially life-threatening situation requiring treatment.

7 Dec 2009

Updated results from phase III EXTEND clinical trial of pixantrone released

Cell Therapeutics, Inc. ("CTI") announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London during a session at the 2009 American Society of Hematology ("ASH") Annual Meeting updated results from the pivotal phase III EXTEND (PIX 301) clinical trial of pixantrone (the "PIX 301 EXTEND trial") in relapsed or refractory, aggressive non-Hodgkin's lymphoma ("NHL") patients who have failed 2 or more prior therapies.

7 Dec 2009

Phase I/II clinical trial of Multimeric-001 Universal Flu Vaccine successful

BiondVax Pharmaceuticals Ltd., an Israeli biopharmaceutical company at the forefront of the development of a Universal Influenza Vaccine, announced the success of the Phase I/II clinical trial of the Company's Multimeric-001 Universal Flu Vaccine, in trials conducted at the Sourasky Medical Center in Tel Aviv, Israel.

7 Dec 2009

ChemGenex Pharmaceuticals presents clinical results of Omapro drug at ASH meeting

ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today updated clinical data showing that Omapro™ (omacetaxine mepesuccinate) produced durable hematologic and cytogenetic responses in chronic myeloid leukemia (CML) patients who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.

7 Dec 2009

Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced

Gloucester Pharmaceuticals announced today the presentation of preclinical data demonstrating that the combination of ISTODAX® (romidepsin) and Velcade® (bortezomib) resulted in synergistic anti-tumor activity in B-cell non-Hodgkin's lymphoma cell lines.

7 Dec 2009

New three-drug combination may be effective for treating patients with bone cancer

A new three-drug combination has shown in a phase 1/2 clinical trial that it is a "highly effective regimen" in the treatment of patients newly diagnosed with multiple myeloma, a cancer of white blood cells in bone marrow, say researchers from Dana-Farber Cancer Institute.

7 Dec 2009

Scientists identify aggression-promoting pheromone in flies’ antenna

Have you ever found yourself struggling to get your order taken at a crowded bar or lunch counter, only to walk away in disgust as more aggressive customers elbow their way to the front? It turns out that flies do much the same thing, according to biologists from the California Institute of Technology (Caltech).

7 Dec 2009

Scientists explore new strategies for treating neurodegenerative diseases

Studies with fruit flies have shown that the specialized nerve cells called neurons can rebuild themselves after injury.

7 Dec 2009

Salon Leau hosts hair service event to support childhood cancer research

To make a difference in the fight against cancer and other terminal illnesses affecting children. All proceeds from each hair service given will be donated to St. Jude Children's Research Hospital.

7 Dec 2009

Medical News

Dabigatran etexilate prevents recurrent VTE with less bleeding than warfarin

New oral drug is safe and effective to combat clotting disorder

Galapagos NV issues new shares

UHC recognizes 10 AMC members for their achievements in Supply Chain Optimization Program

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

J&JPRD announces clinical results of new oral anticoagulant therapy for venous thromboembolism

Computer search algorithms identify FDA-approved drugs that could be the basis for new medicines

AHF hosts free rapid HIV testing in conjunction with Faithful Central Bible Church

CDC announces the start of National Influenza Vaccination Week

Positive clinical data from Phase II study of elacytarabine in patients with AML reported

SU2C awards $9.68 million to support high-risk cancer research

Anticoagulants used to prevent clots in placental blood vessels ineffective, reveals research

Updated results from phase III EXTEND clinical trial of pixantrone released

Phase I/II clinical trial of Multimeric-001 Universal Flu Vaccine successful

ChemGenex Pharmaceuticals presents clinical results of Omapro drug at ASH meeting

Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced

New three-drug combination may be effective for treating patients with bone cancer

Scientists identify aggression-promoting pheromone in flies’ antenna

Scientists explore new strategies for treating neurodegenerative diseases

Salon Leau hosts hair service event to support childhood cancer research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News